Neuroblastoma – Causes, Symptoms and Treatment
Neuroblastoma is a malignant tumor arising from immature nerve cells of the sympathetic nervous system, most commonly affecting young children and often originating in the adrenal medulla.
Things worth knowing about "Neuroblastoma"
Neuroblastoma is a malignant tumor arising from immature nerve cells of the sympathetic nervous system, most commonly affecting young children and often originating in the adrenal medulla.
What is Neuroblastoma?
Neuroblastoma is a malignant (cancerous) tumor that develops from immature nerve cells of the sympathetic nervous system. It is one of the most common solid extracranial tumors in childhood, accounting for approximately 8–10% of all childhood cancers. The tumor most frequently arises in the adrenal medulla, but it can develop anywhere along the sympathetic nerve chain — including the abdomen, chest, or neck.
Causes and Risk Factors
The exact causes of neuroblastoma are not yet fully understood. In most cases, the disease occurs sporadically, without a family history. In approximately 1–2% of cases, a hereditary form is present, associated with mutations in the ALK gene (Anaplastic Lymphoma Kinase) or the PHOX2B gene.
- Genetic predisposition (familial neuroblastoma)
- Mutations in the ALK or PHOX2B genes
- Amplification of the MYCN oncogene (associated with more aggressive disease)
Symptoms
Symptoms depend on the location of the tumor and its extent of spread. Neuroblastoma is often not detected until it has already metastasized (spread to other parts of the body).
- Palpable lump or swelling in the abdomen
- Abdominal pain or a sensation of fullness
- Bone pain (due to metastases)
- High blood pressure and rapid heartbeat (due to catecholamine secretion)
- Pallor, fatigue, and weight loss
- Periorbital bruising (so-called raccoon eyes) when metastases affect the eye socket
- Breathing difficulties with thoracic (chest) tumors
Diagnosis
Diagnosis of neuroblastoma involves a combination of investigative methods:
Imaging Studies
- Ultrasound: Initial investigation for a suspected abdominal mass
- CT (Computed Tomography) and MRI (Magnetic Resonance Imaging): For precise localization and assessment of extent
- MIBG scintigraphy (Meta-Iodobenzylguanidine): A specialized nuclear medicine scan that reliably detects neuroblastoma cells
- PET-CT: Used for MIBG-negative tumors
Laboratory Tests
- Measurement of catecholamines and their metabolites (vanillylmandelic acid, homovanillic acid) in urine
- NSE (Neuron-Specific Enolase) and LDH (Lactate Dehydrogenase) in blood as tumor markers
Tissue Biopsy
A biopsy of the tumor tissue is obtained for definitive diagnosis and tumor typing, including histological (microscopic tissue) examination. MYCN amplification status is also determined, as it has significant implications for treatment and prognosis.
Staging
Neuroblastomas are classified using the international INRG (International Neuroblastoma Risk Group) system into risk categories: very low, low, intermediate, and high. This classification is based on age, tumor stage, MYCN status, histology, and additional molecular markers.
Treatment
Treatment is guided by the patient's risk group and may include the following approaches:
Low-Risk Neuroblastoma
In very young infants with low-risk disease, a watchful waiting approach may be sufficient, as some tumors regress spontaneously. Surgical removal is performed if necessary.
Intermediate Risk
- Surgical removal of the tumor (resection)
- Moderate chemotherapy
High-Risk Neuroblastoma
- Intensive induction chemotherapy to reduce tumor size
- Surgical resection of residual tumor
- High-dose chemotherapy followed by autologous stem cell transplantation
- Radiotherapy to the tumor bed
- Immunotherapy with the antibody Dinutuximab (targeting the ganglioside GD2 on neuroblastoma cells)
- Isotretinoin (13-cis-retinoic acid) as differentiation therapy
Prognosis
Prognosis depends strongly on the risk group. Children with low-risk neuroblastoma have excellent survival rates of over 90%. In high-risk neuroblastoma, long-term survival rates remain approximately 40–50% despite intensive therapy. Ongoing clinical trials are investigating new approaches such as targeted therapies (ALK inhibitors) and CAR-T cell therapies to further improve outcomes.
References
- Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nature Reviews Clinical Oncology, 2014; 11(12): 704–713.
- Matthay KK et al. Neuroblastoma. Nature Reviews Disease Primers, 2016; 2: 16078.
- Maris JM. Recent advances in neuroblastoma. New England Journal of Medicine, 2010; 362(23): 2202–2211.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryCountertransference
Resource Activation
Chlorine dioxide
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Neuroblastoma-en